The physiological effects of insulin-like growth factor I (IGF-I) on intermediate metabolism of substrates have been extensively studied in a variety of experimental situations in man, and its effects on linear growth of children with GH receptor mutations have proven beneficial. However, there is a paucity of data on the metabolic effects of IGF-I as replacement therapy in adults with GH receptor deficiency (Laron's syndrome). We designed these studies to investigate the in vivo effects of 8 weeks of therapy with recombinant human IGF-I (rhIGF-I) in a unique group of 10 adult subjects with profound IGF-I deficiency due to a mutation in the GH receptor gene (mean Ϯ SEM age, 29.2 Ϯ 2.0 yr; 4 males and 6 females). At baseline, patients had infusions of stable tracers, including L-[
T HE METABOLIC actions of insulin-like growth factor I
(IGF-I) are complex, with both GH-like and insulin-like effects in vivo depending on the dose used and the mode of administration (1) . IGF-I has been clearly shown to mediate many of the growth-promoting effects of GH (2, 3) , congruent with the somatomedin hypothesis. In lower doses, it also mediates the protein anabolic actions of GH by selectively increasing whole body protein synthesis without affecting rates of proteolysis, whereas in higher doses it suppresses proteolysis, similar to an insulin-like effect (4, 5) . The effects of IGF-I on carbohydrate metabolism are also dose related, resulting in a suppression of circulating insulin, yet maintenance of normoglycemia, and in higher doses it can cause marked hypoglycemia, evidence of an insulin-like effect of the peptide (4, 6) . The latter effect is mediated either through the insulin receptor or through its own, type 1 IGF-I receptor (7, 8) . The effects of IGF-I on lipolysis have also been observed to be dependent on the length of treatment, with both increased and decreased lipid oxidation rates observed after IGF-I administration (9, 10) . IGF-I, however, does not mediate the lipolytic effect of GH, as there are no functional type 1 IGF-I receptors in the adipocyte (11) . Interestingly, we observed a clear dichotomy of the effects of IGF-I in vivo depending on the mode of delivery. There was marked enhancement of the rates of protein synthesis when recombinant human IGF-I (rhIGF-I) was given for 5-7 days as two sc injections, yet no effect on whole body protein was observed when it was administered as a continuous sc infusion for 16 h/day (9) ; both delivery strategies, however, had a marked impact, enhancing carbohydrate oxidation rates, indicating the differential sensitivity to the metabolic effects of this peptide.
RhIGF-I has been successfully used to promote linear growth in children with GH insensitivity (Laron's syndrome) (2, 3) . This condition manifests as profound IGF-I deficiency despite normal or high circulating GH concentrations due to a variety of mutations in the GH receptor gene (12) (13) (14) . These patients' physical, biochemical, and linear growth responses to rhIGF-I have been extensively characterized previously both in short term metabolic studies and in long term studies assessing linear growth (2, 3, (15) (16) (17) (18) (19) . The metabolic effects of GH in the adult with GH deficiency (GHD), the increase in lean body mass, the decrease in adiposity, and the positive cardiovascular/lipid effects, are substantial and have led to the common use of GH in adults with GHD in most western countries (20, 21) . Even though the benefit of rhIGF-I treatment promoting linear growth in children with homozygous forms of GH receptor deficiency (GHRD) has been clearly established, the long term use of this peptide for purposes other than linear growth has been less well characterized in the adult (22) . We designed these studies to assess the effects of rhIGF-I on protein, glucose, and lipid metabolism and on body composition in a unique population of adult subjects with a homozygous mutation in the GH receptor gene resulting in Laron's syndrome. Contemporary, stable tracer methodologies were used to study intermediate metabolism before and after more prolonged (8-week) administration of rhIGF-I.
Subjects and Methods

Study subjects
These studies were approved by the clinical research review committee at the Nemours Children's Clinic, the General Clinical Research Center (CRC) advisory committee at the Mayo Clinic (Rochester, MN), the institutional review board at Baptist Medical Center/Wolfson Children's Hospital (Jacksonville, FL) where these studies were conducted, and the institutional review board at the Institute for Endocrinology and Reproduction (Quito, Ecuador). Subjects were recruited after informed written consent was obtained verbally and in writing in Spanish, the subjects' native language. A group of 10 adult subjects was recruited by Dr. Guevara-Aguirre in Ecuador, all of whom had been previously identified to be homozygous for the alternative splice site mutation of codon 180 of exon 6 of the GH receptor gene and profound short stature. The genetic, biochemical, and physical characteristics of this patient population have been extensively studied previously (12, 13, 17, 19) . Subjects were all in good health, were taking no chronic medications, and had not received any rhIGF-I for at least 3 yr before these studies. Their clinical characteristics are summarized in Table 1 .
Study design
Subjects traveled in two groups of five with their physicians from Quito to Jacksonville twice over the 10 weeks of these experiments. A full physical exam was performed, and routine blood chemistries and cell counts were made upon arrival at our research center. For 3 days before admission to the Wolfson Children's Hospital CRC they consumed a weight maintenance diet based upon the dietary histories obtained by the research dietitian consisting of about 30 Cal/kg and 1 g/kg protein⅐day.
The afternoon before the first study (D1) the subjects were admitted to the Wolfson Children's Hospital CRC. Assessment of body composition was obtained using skinfold calipers, bioelectrical impedance analysis, as well as dual emission x-ray absorptiometry (DEXA), using a tissue bar (Hologic 2000, Hologic, Inc., Waltham, MA). Dinner was served at 1800 h; subsequently, the patients were fasted except for water ad libitum until the completion of the studies at 1300 h the next day. The next morning (baseline study) at 0600 h, two antecubital veins were cannulated after numbing the skin with an anesthetic cream (EMLA, AstraZeneca, Wilmington, DE). One cannula was kept heated for arterialized blood sampling (23) . At 0800 h (time zero), three stable isotope tracers were given. One, a primed, dose constant infusion of l-[1- . Frequent blood samples were collected for determination of the isotopic enrichment of the different tracers in plasma as well as the concentrations of hormones, substrates, and growth factors, as detailed below. Frequent breath samples were also obtained for determination of 13 CO 2 enrichment in expired breath. Indirect calorimetry was performed three times during the 4 h of isotope infusion using a mouth piece and a CPX max indirect calorimeter (Medical Graphics, St. Paul, MN). After the isotope infusions were completed, the patients were fed lunch and discharged from the unit.
After the baseline study, all subjects returned to Ecuador and were begun on rhIGF-I at a dose of 60 g/kg, sc, twice daily; they were closely monitored for the first 24 h by the physician team in Ecuador. They were then sent home and continued to take twice daily injections of rhIGF-I. Subjects were instructed to monitor their blood glucose concentrations using home glucose monitoring equipment for the first week after initiation of rhIGF-I therapy and any other time there were any symptoms of hypoglycemia. They were also instructed to take the rhIGF-I injection with their meals to avoid hypoglycemia.
After 8 weeks, the subjects flew back to the CRC in Jacksonville where the studies were repeated identically as at baseline (D2). The only difference was that the night before the second study, starting at 2000 h, the second dose of rhIGF-I was substituted for a continuous sc infusion of the peptide at 10 g/kg⅐h using an insulin delivery pump (MiniMed, Inc., Sylmar, CA), which was continued uninterrupted for the next 16 h until the completion of the studies the following morning. This was performed to prevent hypoglycemia during the administration of rhIGF-I while the patients were fasting, while maintaining plasma IGF-I concentrations constant. We have successfully used this strategy in similar experiments previously (4, 9, 24) . Each patient served as his/her own control. Plasma IGF-I, IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-2, IGFBP-3, insulin, and glucose concentrations were measured three times at 0, 120, and 240 min during the tracer infusions. Serum GH concentrations were measured at hourly intervals for the 4 h of the studies. ␤-Hydroxybutyrate and free fatty acid concentrations were measured in plasma samples at Ϫ20 and 120 min. Serum lipids were also measured while fasting on each study day. Breath samples were obtained for the measurement of expired labeled CO 2 at Ϫ20, Ϫ10, Ϫ5, 160, 180, 200, and 220 min. A small aliquot of the urine collected during the 4 h of the morning study was used for determination of the urea nitrogen concentration.
Assays. Plasma enrichments of [
13 C]KIC, [ 2 H 2 ]glucose, and d 5 -glycerol were determined at the Nemours metabolic core laboratory by gas chromatography mass spectrometry as previously described (25, 26) . 13 CO 2 was measured by isotope ratio mass spectrometer as described previously (27) . All insulin and lipid concentrations were run at the immunochemical core laboratory at the Mayo Clinic General Clinical Research Center (Rochester, MN) using commercial kits; IGF-I, IGFBP-1, IGFBP-2, IGFBP-3, and IGF-II concentrations were measured by radioimmunometric assays. ␤-Hydroxybutyrate concentrations were measured at the Nemours biochemical analysis laboratory by spectrophotometric enzymatic determination using kits from Sigma (St. Louis, MO), and free fatty acid concentrations were measured by calorimetric methods using kits purchased from Roche Molecular Biochemicals (Indianapolis, IN). Serum GH concentrations were measured by a highly sensitive chemiluminescence assay at the University of Virginia CRC core laboratory (Charlottesville, VA). Plasma glucose concentrations were measured by a glucose oxidase method using a glucose analyzer (Beckman Coulter, Inc., Palo Alto, CA) at the bedside. Serum lipids [cholesterol, triglycerides, high density lipoprotein (HDL), and low density lipoprotein (LDL)] concentrations were measured by high performance liquid chromatography methods. Urea nitrogen was measured using a Kodak Ektakem urease method (Eastman Kodak Co., Rochester, NY).
Calculations. The reciprocal pool model was used to estimate rates of whole body protein turnover at steady state as previously described (28) . The rate of appearance (Ra) of glucose, a measure of hepatic glucose output, as well as that of glycerol were calculated as:
where Ei is the isotopic enrichment of the infusate, Ep is the enrichment of glucose or glycerol in plasma, and F is the infusion rate. Substrate oxidation rates for protein, glucose, and lipid and resting energy expenditure were calculated using the rate of gas exchange (VO 2 and VCO 2 ) from indirect calorimetry as previously described (29) .
Fat-free mass (FFM) and percent fat mass (FM) were measured using DEXA and the tissue bar as well as by the sum of skin folds as described previously (30) .
Isotopes and drugs. l-[1-
13 C]Leucine and d 5 -glycerol (both 99% enriched; Cambridge Isotopes, Andover, MA) and [6,6-2 H 2 ]glucose (99.7% enriched; MSD Isotopes, St. Louis, MO) were determined to be sterile and pyrogen free and were mixed with 0.9% nonbacteriostatic saline. rhIGF-I (10 mg/ml) was provided by Genentech, Inc. (South San Francisco, CA).
Statistical analysis.
Results are expressed as the mean Ϯ se. Paired Student's t test was used to estimate differences between baseline studies and rhIGF-I and rhGH treatments for all parameters tested. Wilcoxon signed ranks test was used for those parameters with results not normally distributed. Significance was established at P Ͻ 0.05. Table 2 summarizes the changes in circulating plasma growth factors before and after rhIGF-I in the 10 subjects with GH receptor mutations. There was a significant increase in plasma IGF-I concentrations during rhIGF-I treatment and a reciprocal decrease in circulating GH concentrations. Even though most patients raised their plasma IGF-I concentrations to the normal range (normative data: males, 155-432 g/L; females, 87-368), 3 did not restore it fully (male subject, from 5 to 133; male, 6 to 113; female, 5 to 76; Fig. 1 ). IGFBP-1 and -2 concentrations increased, IGFBP-3 did not change, and IGF-II concentrations decreased during treatment. Table 3 summarizes the changes in body composition and protein kinetics observed during treatment. There were no changes in body weight during rhIGF-I treatment. There were, however, subtle, yet significant, changes in body composition as measured by DEXA, with a 1-kg increase in FFM (P ϭ 0.001) and a corresponding decrease in percent FM after 8 weeks of treatment (P ϭ 0.003).
Results
Hormones and growth factors
Body composition and protein metabolism
The Ra of leucine, a measure of proteolysis, was increased in these subjects after rhIGF-I treatment, leucine oxidation rates decreased, with an overall increase in the nonoxidative leucine disposal (NOLD), a measure of whole body protein synthesis. These findings were also observed when the data were expressed per kg FFM (data not shown).
Fat metabolism
All measures of lipolytic activity and lipid oxidation were increased after 8 weeks of rhIGF-I therapy. There was an 18% increase in the Ra of glycerol, a measure of whole body lipolysis, from 2.51 Ϯ 0.13 m/kg⅐min on D1 to 2.96 Ϯ 0.21 on D2 (P ϭ 0.06) or, when expressed per kg FM, from 5.77 Ϯ 0.58 mol/kg FM⅐min on D1 to 7.06 Ϯ 0.79 on D2 (P ϭ 0.04). Fasting plasma free fatty acid concentrations increased after rhIGF-I administration from 0.34 Ϯ 0.04 mmol/L to 0.42 Ϯ 0.06 (P ϭ 0.06), and ␤-hydroxybutyrate from 0.50 Ϯ 0.20 mg/dL to 1.70 Ϯ 0.50 (P ϭ 0.02). Using gas exchange mea-
TABLE 2. Hormones and growth factors of subjects with GH receptor deficiency before (D1) and after 8 weeks of rhIGF-I administration (D2)
Normal concentrations for adult subjects are shown in (brackets) under the given growth factor. The range of GH concentrations observed in these subjects is given in parentheses under columns D1 and D2. surements via indirect calorimetry, lipid oxidation rates increased from 19.2 Ϯ 3.8 Cal/FFM⅐day to 27.6 Ϯ 4.4 (P ϭ 0.04; Fig. 2 ). Plasma lipid concentrations remained invariant during rhIGF-I treatment: total cholesterol, 179 Ϯ 11 mg/dL on D1 and 176 Ϯ 11 on D2; HDL, 47 Ϯ 3 mg/dL on D1 and 46 Ϯ 4 on D2; LDL, 112 Ϯ 10 mg/dL on D1 and 109 Ϯ 8 on D2; triglycerides, 100 Ϯ 15 mg/dL on D1 and 106 Ϯ 24 on D2 (P ϭ NS for all comparisons).
Glucose metabolism
There was maintenance of normoglycemia despite suppression of circulating insulin concentrations in the fasted state after rhIGF-I therapy: plasma glucose concentrations: D1, 88 Ϯ 2 mg/dL; D2, 88 Ϯ 4 (or D1, 4.9 Ϯ 0.1 mmol/L; D2, 4.9 Ϯ 0.2); insulin concentrations: D1, 5.4 Ϯ 1.5 U/mL; D2, 2.4 Ϯ 0.7 (P ϭ 0.01; or D1, 32.4 Ϯ 9.0 pmol/L; D2, 14.4 Ϯ 4.2). Glucose Ra, a measure of hepatic glucose production, was increased after rhIGF-I therapy from 1.95 Ϯ 0.15 mg/kg⅐min to 2.36 Ϯ 0.18 (P ϭ 0.00001). Glucose oxidation rates were decreased from 25 Ϯ 4 Cal/FFM⅐day to 17 Ϯ 5 (P ϭ 0.04) after chronic rhIGF-I therapy.
Comparison with GHD and normal subjects
Some of the responses of the subjects with GHRD to rhIGF-I were compared with those of a group of 8 GHD adults treated with rhGH (12.5 g/kg⅐day, sc) and rhIGF-I (60 g/kg twice daily, sc) for 8 weeks, each reported previously [mean age, 23.5 Ϯ 2.1 yr; 6 males and 2 females; body mass index (BMI), 28.2 Ϯ 2.2 kg/m 2 ] (31). Data were also compared with those of a group of 10 healthy males (mean age, 23.7 Ϯ 0.5 yr; BMI, 25.2 Ϯ 0.9 kg/m 2 ) who participated in similar studies, some of which have been reported previously (32) . The data from the experiments were gathered identically as in the present GHRD subjects. Figure 3 , left panel, shows the changes in IGF-I concentrations in the 3 groups of subjects, the right panel shows the fasting insulin concentrations, and Fig. 4 shows the rates of nonoxidative leucine disposal, a measure of whole body protein synthesis. 
Safety profile
These doses of rhIGF-I were well tolerated in all subjects. After the initiation of treatment there were complaints of occasional headaches, tachychardia, and soft tissue swelling, the latter most likely secondary to fluid retention. These symptoms were all transient and well tolerated. No patient discontinued the medication because of them. General chemistries, blood counts, thyroid profile, and sex steroid concentrations remained invariant during these studies.
Discussion
Relatively short term (8-week) daily administration of rhIGF-I had substantial, positive effects in IGF-I-deficient adults with GH receptor mutations. Rates of protein synthesis increased significantly; body composition changed with increased lean body mass and decreased adiposity without changes in total body weight. Rates of lipolysis and lipid oxidation also increased after rhIGF-I, suggestive of a nutrient shift and a net protein anabolic effect. Glucose production rates increased with long-term treatment, yet there was no hyperglycemia despite persistent insulinopenia. The expected increase in glucose resulting from this increase in hepatic glucose production was probably negated by increased glucose transport, suggestive of a compensatory increase in insulin-like sensitivity during treatment.
These patients with GH receptor mutations had GH concentrations that were significantly suppressed during rhIGF-I treatment, whereas the GH-dependent growth factors were unaltered; hence, they represent a unique biological model that allows the measurement of IGF-I effects without the confounding effects of GH. Treatment with rhIGF-I resulted in normalization of the plasma IGF-I concentrations in most of the subjects studied and a near-normalization in the others, without any measurable alteration in IGFBP-3 concentrations and a marked decline in circulating GH concentrations. These data are similar to previously reported results after short-term treatment with this peptide and after prolonged treatment for linear growth purposes (3, 33) .
The observed changes in body composition, with increased lean body mass and decreased adiposity, were not accompanied by total body weight changes and are remarkable considering that subjects were treated for only 8 weeks. These changes were similar to those observed in GHD patients treated with rhGH and rhIGF-I for 8 weeks, each at similar doses reported by us recently (31) and not dissimilar from those observed after more prolonged treatment with rhGH in adults with GHD (21) . Five adults treated with rhIGF-I at twice the dose used here were also reported to have decreased adiposity, as measured by skinfold thickness, after 6 -9 months (22) . Interestingly, rhIGF-I treatment of Laron's syndrome subjects resulted in increased protein breakdown and protein synthesis rates, with a net protein anabolic effect. These results differ from the selective increase in protein synthesis rates observed after rhIGF-I in healthy individuals (4) and GHD subjects (31) and may be secondary to the chronic relative insulinopenia observed , and in healthy controls (n ϭ 10). The comparisons vs. baseline within each group for IGF-I are: GHRD, P ϭ 0.001; GHD after rhIGF-I, P ϭ 0.002; and GHD after rhGH, P ϭ 0.0001. For insulin concentrations the within-group comparisons are: GHRD, P ϭ 0.01; GHD after rhIGF-I, P ϭ 0.02; and GHD after rhGH, P ϭ 0.001. To covert insulin concentrations to picomoles per L multiply by 6.
FIG. 4.
Comparison of NOLD, a measure of protein synthesis, in the same three groups as those shown in Fig. 3 . The within-group comparisons vs. baseline are: GHRD, P ϭ 0.001; GHRD after rhIGF-I, P ϭ 0.06; and GHRD after rhGH, P ϭ 0.02. during treatment, as insulin administration typically suppresses proteolysis (34) .
The effects of 8 weeks of chronic rhIGF-I treatment on all measures of fat metabolism in this cohort of GHRD subjects is perhaps the most intriguing. Using stable isotopes of glycerol, measurement of glycerol turnover allows the estimation of rates of lipolysis at the whole body level. The breakdown of stored triglyceride in the adipocyte results in the release of both free fatty acids and glycerol, and as there is no glycerol kinase in the adipocyte (hence, reesterification of the released glycerol is not possible within the fat cell), the measurement of the rate of appearance of glycerol is used as a measure of whole body lipolysis. Using this tool, lipolytic rates were increased during rhIGF-I treatment, and this difference was most obvious when the data were expressed per kg FM, highlighting the sensitivity of adipose tissue to the antilipogenic effects of IGF-I. There was minimal change in FFA concentrations, yet the glycerol Ra increased, and as glycerol concentrations did not change, it may be that some of the effect of the treatment was to increase the effectiveness of FFA utilization, such that despite greater release of the products of lipolysis the utilization was increased so as to maintain the same concentration.
Measures of gas exchange and indirect calorimetry in these subjects also revealed a significant increase in the oxidation of lipids; there was also an increase in the concentrations of ketone bodies (␤-hydroxybutyrate), which, taken in aggregate, suggest that not only is there mobilization and breakdown of stored lipids, but there is also increased oxidation of the broken fat. As there appear to be no functional type 1 IGF-I receptors in the adipocyte (11) , and both GH and insulin concentrations are suppressed during rhIGF-I treatment, these data suggest that these effects on fat metabolism are secondary to chronic relative insulin deficiency during rhIGF-I treatment. This is congruent with recent data in rats that show that IGF-I reduces fat mass via inhibition of the lipogenic capacity of adipocytes and inhibition of insulin secretion (35) . Even though the plasma lipid profiles remained unchanged in these subjects during treatment, the beneficial effects of IGF-I replacement on fat metabolism deserve further long-term study.
There was a modest, yet significant, increase in the glucose Ra, a measure of hepatic glucose production, in these patients. This is similar to the increase observed after rhIGF-I treatment of normal (9) and GHD subjects (31, 36) reported by us previously and strongly suggests that there is relative suppression of insulin concentrations at the portal level. The fact that glucose concentrations remained normal and there was no hyperglycemia despite an increase in glucose production rates during these 8-week experiments suggest, however, that IGF-I actively participates in glucose transport. The latter could be either through the insulin receptor (7) or through its own type 1 receptor (8). Di Cola et al. studied insulin receptor-deficient mice and showed that IGF-I caused a prompt and sustained decrease in plasma glucose levels, similar to that in mice with intact insulin receptors (8) . They also observed that in skeletal muscle, IGF-I treatment caused phosphorylation of IGF-I receptors and increased the levels of the phosphatidylinositol-3-kinase p85 subunit, consistent with the possibility that IGF-I stimulates glucose uptake in a phosphatidylinositol-3-kinasedependent manner. It is likely that the sustained glucose transport and persistent normoglycemia observed here reflect this action of rhIGF-I in humans through both the insulin and the IGF-I receptor. Based on these data, the long-term use of rhIGF-I in the adult with GHRD should not have deleterious effects on carbohydrate tolerance. Further studies on long-term safety in the adult are needed.
Compared with GHD subjects reported previously (31) , it appears that the metabolic deficiencies observed are more severe in GHRD states. Even though there are substantial increases in rates of protein synthesis after rhIGF-I, e.g. compared to GHD patients treated with rhGH and rhIGF-I, the best normalization of these rates was observed in the GHD subjects treated with rhGH. It is noticeable that rhIGF-I treatment of the GHD subjects resulted in the largest increase in plasma IGF-I concentrations, followed by rhGH treatment in GHD subjects and lastly rhIGF-I treatment of GHRD patients. There are, however, comparable increases in NOLD per U increase in IGF-I for the GHRD patients treated with rhIGF-I as for the GHD patients treated with rhGH, supportive of the idea that IGF-I mediates the protein anabolic actions of GH in man (4, 24) . Adult GHD subjects treated with rhIGF-I studied by us using the same doses as those reported here showed normal absorption and distribution of IGF-I, yet faster elimination kinetics than normal subjects (37), similar to results observed in GHRD subjects reported previously (38) . However, the rise in plasma IGF-I concentrations observed in this cohort, even though not fully normal in three patients, is appropriate, and the metabolic effects observed are substantial, suggesting that a dose of 60 g/kg twice daily may be appropriate for long-term studies in this patient population. Whether complete normalization of the metabolic derangement of these patients could be overcome with years of rhIGF-I therapy remains to be fully studied. However, considering the pivotal role of this hormone in a multiplicity of metabolic functions in vivo, the actual, albeit limited, availability of this peptide, and the standard practice of endocrinology to replace hormone-deficient states, it behooves us to perform the necessary long-term studies in the affected adults with this syndrome. The ultimate effects on the quality of life of these patients would also need to be assessed.
In conclusion, we studied intermediate metabolism of proteins, sugars, and lipids in a group of severely IGF-I-deficient subjects treated with rhIGF-I for 8 weeks. IGF-I affects protein, glucose, and lipid metabolism independent of GH and has positive anabolic effects in this condition. These results suggest that rhIGF-I may be beneficial for long-term replacement of the adult with Laron's syndrome.
